Abstract
The UK medical research charity LifeArc has sold most of its royalty rights for the antibody pembrolizumab to the Canada Pension Plan Investment Board for $1.3 billion. LifeArc got the royalty for helping develop the antibody with Organon, which Merck & Co. later acquired. Pembrolizumab, now marketed by Merck as Keytruda, brought in sales of $7.2 billion last year. LifeArc chairman John Stageman describes the deal as “a once-in-a-generation opportunity.”
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
